- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07782021
MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease (MIRICURE)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Perianal fistulizing Crohn disease is a severe manifestation of Crohn disease associated with persistent fistula drainage, impaired quality of life, and substantial morbidity. Although biologic therapies have improved outcomes, durable fistula healing remains uncommon, and optimal treatment strategies continue to be defined.
Mirikizumab is an interleukin-23 p19 antagonist approved for the treatment of moderately to severely active Crohn disease. Surgical management, including fistula tract curettage and closure of the internal opening, has demonstrated favorable outcomes when incorporated into multidisciplinary treatment approaches for complex perianal fistulas.
This Phase 4, multicenter, single-arm, open-label study will enroll approximately 50 adults with active complex perianal fistulizing Crohn disease. Participants will undergo examination under anesthesia with fistula tract curettage and seton placement prior to initiation of mirikizumab induction therapy. After 8 to 10 weeks of treatment, participants will undergo repeat examination under anesthesia with seton removal, repeat curettage, and closure of the internal fistula opening. Participants will receive mirikizumab induction followed by maintenance therapy and will be followed for 48 weeks.
Pelvic MRI will be performed at Weeks 12, 24, and 48 and evaluated using standardized MAGNIFI-CD and TOpCLASS criteria. Clinical assessments, patient-reported outcome measures, safety evaluations, and quality-of-life assessments will be collected throughout the study.
The primary objective is to evaluate the proportion of participants achieving combined clinical remission and radiologic response at Week 24. Secondary objectives include evaluation of clinical remission, radiologic remission, fistula healing, quality of life, disease activity, and safety through Week 48.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Serre-Yu Wong, MD, PhD
- Numéro de téléphone: 212-241-3179
- E-mail: serre-yu.wong@mountsinai.org
Lieux d'étude
-
-
Missouri
-
Louis, Missouri, États-Unis, 63130
- Washington University in St. Louis
-
Contact:
- Parakkal Deepak, MBBS, MS
- Numéro de téléphone: 314-273-1947
- E-mail: deepak.parakkal@wustl.edu
-
-
New York
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Serre-Yu Wong, MD, PhD
- Numéro de téléphone: 212-241-3179
- E-mail: serre-yu.wong@mountsinai.org
-
Chercheur principal:
- Serre-Yu Wong, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults ≥18 years
- Diagnosis of Crohn disease for at least 3 months
- Active draining complex perianal fistula
- Able to provide informed consent
Exclusion Criteria:
- Rectovaginal fistula
- Only low intersphincteric or submucosal fistulas
- Severe proctitis preventing surgical closure
- Stoma
- Active tuberculosis
- Active hepatitis B
- Active serious infection
- Pregnancy
- Concurrent investigational drug trial
- MRI contraindication
- Additional laboratory exclusions as specified in the protocol
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Participants with active perianal fistulizing Crohn disease
Participants receive mirikizumab in combination with staged surgical management for active perianal fistulizing Crohn disease.
|
Mirikizumab is administered as a 900 mg intravenous infusion at Weeks 0, 4, and 8, followed by a 300 mg subcutaneous maintenance injection beginning at Week 12 and every 4 weeks thereafter through the end of the study.
Autres noms:
Participants undergo an initial examination under anesthesia with fistula tract curettage and seton placement before initiation of mirikizumab therapy.
After 8 to 10 weeks of induction therapy, participants undergo a second examination under anesthesia with seton removal, repeat fistula tract curettage, and closure of the internal fistula opening(s).
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants achieving combined clinical remission and radiologic response
Délai: Week 24
|
Proportion of participants achieving combined clinical remission and radiologic response. Clinical remission is defined as complete closure of all treated external fistula openings without spontaneous drainage or drainage upon gentle finger compression and without development of new fistulas or abscesses greater than 1 cm. Radiologic response is defined using MAGNIFI-CD criteria as greater than 50% reduction in MAGNIFI-CD score together with improvement in fibrosis-to-fluid ratio compared with baseline MRI. The MAGNIFI-CD is an MRI-based composite index that assesses perianal fistulizing Crohn disease activity using six weighted domains, including fistula complexity, tract length, fistula composition, tract enhancement, extension, and inflammatory mass/abscess. Total scores range from 0 to 25, with higher scores indicating greater disease activity and lower scores indicating improvement. |
Week 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants achieving combined clinical remission and radiologic response
Délai: 48 week
|
Proportion of participants achieving combined clinical remission and radiologic response. Clinical remission is defined as complete closure of all treated external fistula openings without spontaneous drainage or drainage upon gentle finger compression and without development of new fistulas or abscesses greater than 1 cm. Radiologic response is defined using MAGNIFI-CD criteria as greater than 50% reduction in MAGNIFI-CD score together with improvement in fibrosis-to-fluid ratio compared with baseline MRI. The MAGNIFI-CD is an MRI-based composite index that assesses perianal fistulizing Crohn disease activity using six weighted domains, including fistula complexity, tract length, fistula composition, tract enhancement, extension, and inflammatory mass/abscess. Total scores range from 0 to 25, with higher scores indicating greater disease activity and lower scores indicating improvement. |
48 week
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Parakkal Deepak, MBBS, MS, Washington University School of Medicine
- Chercheur principal: Serre-Yu Wong, MD, PhD, Icahn School of Medicine at Mount Sinai
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SW-1
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose.
To achieve aims in the approved proposal. Proposals should be directed to serre-yu.wong@mountsinai.org and deepak.parakkal@wustl.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (TBD).
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .